


### III. CLAIM AMENDMENTS

1-25. (Cancelled)

26. (New) Use of at least one of the 2,5-dihydroxybenzenesulfonic compounds of general formula I,



wherein

R represents H or  $\text{SO}_3^-$ ,

B represents at least one cation

n represents 1 or 2

m represents 1 or 2,

optionally in form of a pharmaceutically acceptable solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of sexual dysfunction in humans, whereby the medicament is administered in a daily dose of the aforementioned compounds of formula I of <500 mg.

27. (New) Use according to claim 26, characterised in that the cation(s) B is (are) selected from the group consisting of  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Na}^+$ ,  $\text{K}^+$  and  $[\text{NH}_4\text{-}_x\text{R}_x]^+$ , whereby x is 0, 1, 2, 3, or 4 and R represents a branched or unbranched  $\text{C}_{1-4}$ -alkyl-radical that may be the same or different for  $x > 1$ .

28. (New) Use according to claim 26, characterized in that the compound of general formula I is calcium 2,5-dihydroxybenzenesulfonate (calcium-dobesilate).

29. (New) Use according to claim 26, characterized in that the compound of general formula I is diethylamine 2,5-dihydroxybenzenesulfonate (ethamsylate).

30. (New) Use according to claim 26, characterized in that the compound of general formula I is bis(diethylamine)-2,5-dihydroxybenzene-1,4-disulfonate (persilate).

31. (New) Use according to claim 26, characterized in that medicament is administered in a daily dose of compounds of general formula I of 100 to <500 mg, preferably 150 to 450 mg, particularly preferably 200 to 400 mg.

32. (New) Use according to claim 26 for the prophylaxis and/or treatment of erectile dysfunction.

33. (New) Use according to claim 26, characterized in that the medicament is suitable for oral administration.

34. (New) Use according to claim 33, characterized in that the medicament is in the form of a tablet, a capsule or a suspension.

35. (New) Use according to claim 33, characterized in that the medicament is in form of multiparticulates, preferably pellets or granules, optionally compressed into a tablet, filled into a capsule or suspended in a suitable liquid.

36. (New) Use according to claim 26, characterized in that the medicament comprises at least one of the compounds of general formula I at least partially in a sustained-release form.

37. (New) Use according to claim 36, characterized in that the medicament has at least one coating or matrix comprising at least one sustained-release material.

38. (New) Use according to claim 37, characterized in that the sustained-release material is based on an optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural, semisynthetic or synthetic wax or fat or fatty alcohol or fatty acid, or on a mixture of at least two of these afore mentioned components.

39. (New) Use according to claim 38, characterized in that the water-insoluble polymer is based on an acrylic resin, which is preferably selected from the group of poly(meth)acrylates, poly(C<sub>1-4</sub>)dialkylamino(C<sub>1-4</sub>)alkyl (meth) acrylates and/or copolymers thereof or a mixture of at least two of the aforementioned polymers.

40. (New) Use according to claim 38, characterized in that the water-insoluble polymers are cellulose derivatives, preferably alkyl cellulose and particularly preferably ethyl cellulose, or cellulose esters.

41. (New) Use according to claim 38, characterized in that the wax is carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.

42. (New) Use according to claim 38, characterized in that the polymers have been used in combination with one or more plasticizers.

43. (New) Use according to claim 32, characterized in that the medicament comprises an enteric coating.

44. (New) Use according to claim 26, characterized in that the medicament comprises at least one immediate-release coating comprising at least one of the compounds of general formula I.